Current Report Filing (8-k)
24 February 2017 - 12:04AM
Edgar (US Regulatory)
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (date of Earliest Event Reported): February 21, 2017
moleculin
biotech, INC.
(Exact Name of Registrant as Specified in
its Charter)
DELAWARE
|
001-37758
|
47-4671997
|
(State or Other Jurisdiction of Incorporation or Organization)
|
(Commission File No.)
|
(I.R.S. Employer Identification No.)
|
2575
WEST BELLFORT, SUITE 333, HOUSTON TX 77054
(Address of principal executive offices
and zip code)
(713) 300-5160
(Registrant’s telephone number, including
area code)
(Former name or former address, if changed
from last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(
see
General Instruction A.2. below):
¨
Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).
|
Item 4.01
|
Changes in Registrant's Certifying Accountant.
|
(a) On February 21,
2017, the Audit Committee of the Board of Directors (the “Audit Committee”) of Moleculin Biotech, Inc. (the “Company”),
dismissed GBH CPAs, PC (“GBH”) as its independent registered public accounting firm, effective as of such date.
The report of GBH on
the Company’s financial statements as of December 31, 2015 and for the period from July 28, 2015 (inception)
to December 31, 2015 and the financial statements of Moleculin, LLC as of and for the years ended December 31, 2015 and 2014 did
not contain an adverse opinion or disclaimer of opinion, and was not qualified or modified as to uncertainty, audit scope, or accounting
principles, other than an explanatory paragraph relating to the Company’s ability to continue as a going concern. During
the year ended December 31, 2015 and through February 21, 2017 there were no: (1) disagreements (as defined in Item 304(a)(1)(iv)
of Regulation S-K and the related instructions to Item 304 of Regulation S-K) with GBH on any matter of accounting principles or
practices, financial statement disclosure, or auditing scope or procedures, which disagreements, if not resolved to the satisfaction
of GBH, would have caused GBH to make reference to the matter in its report on the financial statements for such year.
The Company has provided
GBH with a copy of the foregoing disclosures and requested that it furnish a letter to the Securities and Exchange Commission stating
whether or not it agrees with the above statements, and, if not, stating the respects in which it does not agree. A copy of such
letter is filed as Exhibit 16.1 to this Current Report on Form 8-K.
(b) On February 21,
2017, the Audit Committee approved the appointment of Grant Thornton LLP (“GT”) as the Company’s independent
registered public accounting firm for the fiscal year ended December 31, 2016.
During the period from
July 28, 2015 (inception) to December 31, 2015, and through February 21, 2017, neither the Company nor anyone on their behalf consulted
with GT with respect to either (i) the application of accounting principles to a specific transaction, either completed or proposed,
or the type of audit opinion that might be rendered on the Company’s financial statements, and neither written nor oral advice
was provided to the Company that GT concluded was an important factor considered by the Company in reaching a decision as to any
accounting, auditing or financial reporting issue; (ii) any matter that was either the subject of disagreement (as defined in Item
304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 of Regulation S-K) or a reportable event (as described
in Item 304(a)(1)(v) of Regulation S-K).
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
|
16.1
|
Letter dated February 22, 2017 from GBH CPAs, PC to the
Securities and Exchange Commission.
|
SIGNATURE
Pursuant to the requirements
of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
MOLECULIN BIOTECH, INC.
|
|
|
|
|
|
|
Date: February 22, 2017
|
|
|
By:
/s/ Jonathan Foster
|
|
Jonathan Foster
|
|
Chief Financial Officer
|
EXHIBIT INDEX
|
16.1
|
Letter dated February 22, 2017 from GBH CPAs, PC to the
Securities and Exchange Commission.
|
Moleculin Biotech (NASDAQ:MBRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Moleculin Biotech (NASDAQ:MBRX)
Historical Stock Chart
From Apr 2023 to Apr 2024